Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.60 |
| ▸ | CMA1 | P23946 | 2/20 | 0.60 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847559 | 0.84 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL153860 | 0.84 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL16050307 | 0.84 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL4500799 | 0.84 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL4297332 | 0.84 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL30224280 | 0.84 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL31010750 | 0.84 | AHR (0.59) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL31040248 | 0.80 | AHR (0.49) | AHRCMA1EIF2AK2PDE3BPDE3A | |
| SCHEMBL3205007 | 0.80 | AHR (0.49) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL31335802 | 0.80 | AHR (0.49) | AHRCMA1EIF2AK2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | disclosed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | AHR 3763/4885CMA1 342/4885EIF2AK2 2538/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | AHR 2669/4885CMA1 247/4885EIF2AK2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.